Abstract:Objective To establish population pharmacokinetic (PPK) models with valproic acid (VPA) in different age groups (infant and toddler,preschool age,school age and adolescence) of Chinese epileptic children by nonlinear mixed effect modeling (NONMEM),and provide evidence for individualized drug therapy.Methods Cases of 518 epileptic children were collected from 2010 to 2013 in the Pediatric Outpatient Clinics of the First Hospital,Peking University.The clinical information included demographic data,medication,serum concentration data and blood biochemical parameters.The patients were divided into infants and toddlers (n =191),children at preschool age (n =172) and children at school and adolescence age (n =155).A total of 665 steady-state serum trough concentration samples were extracted.Population pharmacokinetic models of VPA were established by NONMEM program by using first-order absorption and elimination.Demography and drug combination was investigated for influence on apparent clearance (CL/F) and apparent volume of distribution (V/F).The reliability and stability of the PPK models were evaluated by 1 000 times of Bootstrap procedure.To assess the accuracy and precision of the different age groups models and whole age model,the average prediction error (MPE),average absolute error (MAE) and average root variance (RMSE) were compared.Results The final model of VPA in different age groups and whole age group were:1.the infant and toddler's age group CL/F (L/h) =0.154 × (WEIG/11.5) 1.31,V/F (L) =3.32 × (WEIG/11.5)2.49.2.preschool age group CL/F (L/h) =0.211 × (WEIG/18)0.534,V/F (L) =4.08.3.school and adolescence age group CL/F (L/h) =0.287 × (WEIG/29.75)0.464,V/F (L) =7.05.4.whole age group CL/F (L/h) =0.197 × (WEIG/18)0.648 × 1.09CEND,V/F (L) =4.25 × (WEIG/18) 0.714 (GEND was gender,male =1,female =0; WEIG was weight).The results of Bootstrap procedure were corresponding to the estimates from NONMEM.The values of the different age groups model MPE,MAE,RMSE were less than ones of the whole age group,which suggested the different age groups models had better precision and accuracy than the whole age group models.Conclusions PPK models of VPA in different age groups of Chinese epileptic children by NONMEM were successfully established.Weight was identified as a significant covariate on VPA clearance.Compared with the whole age group models,the different age groups models are more reliable.

Improving the Accuracy of Pediatric Pharmacokinetics Parameter Estimates: a Case Study of Oseltamivir

Application of Ivive and Pbpk Modeling in Prospective Prediction of Clinical Pharmacokinetics: Strategy and Approach During the Drug Discovery Phase with Four Case Studies

Development of a Virtual Chinese Pediatric Population Physiological Model Targeting Specific Metabolism and Kidney Elimination Pathways

A Computational Method to Quantitatively Measure Pediatric Drug Safety Using Electronic Medical Records

Application of a Physiologically Based Pharmacokinetic Model to Characterize Time-dependent Metabolism of Voriconazole in Children and Support Dose Optimization

Simulation of the Pharmacokinetics of Oseltamivir and Its Active Metabolite in Normal Populations and Patients with Hepatic Cirrhosis Using Physiologically Based Pharmacokinetic Modeling

Modeling Approach to Optimizing Dose Regimen of Vancomycin for Chinese Pediatric Patients with Gram-Positive Bacterial Infections.

Population Pharmacokinetics Of Vancomycin In Chinese Pediatric Patients

Prediction of Pediatric Pharmacokinetics for CYP3A4 Metabolized Drugs: Comparison of the Performance of Two Hepatic Ontogeny Within a Physiologically Based Pharmacokinetic Model

Population Pharmacokinetics Modeling of Vancomycin Among Chinese Infants With Normal and Augmented Renal Function

Population pharmacokinetic analysis for dose regimen optimization of vancomycin in Southern Chinese children

Establishment of Population Pharmacokinetic Models with Valproic Acid in Different Age Groups of Chinese Epileptic Children

Population Pharmacokinetic Analysis of Amikacin and Validation on Neonates Using Monte Carlo Method.

Evaluation and optimization of sample size of neonates and infants for pediatric clinical studies on cefiderocol using a model‐based approach

Predictive Performance of Physiologically Based Pharmacokinetic and Population Pharmacokinetic Modeling of Renally Cleared Drugs in Children

Evaluation of the population pharmacokinetic models of vancomycin in geriatric patients

Establishment and Evaluation of a Parametric Population Pharmacokinetic Model Repository for Ganciclovir and Valganciclovir.

Bayesian design using adult data to augment pediatric trials

Influences of renal function descriptors on population pharmacokinetic modeling of vancomycin in Chinese adult patients

Development of a Physiologically Based Pharmacokinetic (PBPK) Population Model for Chinese Elderly Subjects

A simulation study of sampling time point designing for therapeutic drug monitoring based on a population pharmacokinetic model